Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8934 results

  1. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  2. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  3. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

  4. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

    Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.

  5. Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

    NICE is unable to recommend panitumumab with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.

    Sections for TA240

  6. Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

    NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.

    Sections for TA353

  7. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 February 2026.

  8. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  9. CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours

    Topic prioritisation

  10. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

  11. AHEAD implants for external ear prosthesis

    Topic prioritisation

  12. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

  13. Insertion of Stoma Preservation Device

    Topic prioritisation

  14. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

  15. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation